Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Lymphoma 3Multiple Myeloma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 6Gemcitabine 6Taxes 3Nivolumab 3Cyclophosphamide 3Capecitabine 3Albumin-Bound Paclitaxel 3trametinib 2ruxolitinib 2pertuzumab 2palbociclib 2olaparib 2fludarabine 2entrectinib 2entinostat 2dabrafenib 2copanlisib 2abiraterone 2Vorinostat 2Sunitinib 2Specimen Handling 2Sirolimus 2Paclitaxel 2Leucovorin 2Ipilimumab 2Immunoglobulin G 2HhAntag691 2Fluorouracil 2Drug Therapy 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × marizomib × Lymphoid × Clear all
NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Celgene

Phase 1 Completed
22 enrolled
DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡